These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Bevacizumab in therapy-refractory epistaxis: case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia]. Rohrmeier C; Kühnel TS HNO; 2012 Nov; 60(11):1003-6. PubMed ID: 22706563 [TBL] [Abstract][Full Text] [Related]
4. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia. Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219 [TBL] [Abstract][Full Text] [Related]
5. Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia. Amann A; Steiner N; Gunsilius E Wien Klin Wochenschr; 2015 Aug; 127(15-16):631-4. PubMed ID: 25986996 [TBL] [Abstract][Full Text] [Related]
6. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia. Epperla N; Hocking W Clin Med Res; 2015 Mar; 13(1):32-5. PubMed ID: 24667223 [TBL] [Abstract][Full Text] [Related]
7. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia. Parambil JG; Woodard TD; Koc ON Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965 [TBL] [Abstract][Full Text] [Related]
8. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia]. Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875 [TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose. Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282 [TBL] [Abstract][Full Text] [Related]
10. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab. Fleagle JM; Bobba RK; Kardinal CG; Freter CE Am J Med Sci; 2012 Mar; 343(3):249-51. PubMed ID: 22227516 [TBL] [Abstract][Full Text] [Related]
11. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646 [TBL] [Abstract][Full Text] [Related]